Nom du produit:ethyl 3-amino-1H-pyrazole-4-carboxylate

IUPAC Name:ethyl 3-amino-1H-pyrazole-4-carboxylate

CAS:6994-25-8
Formule moléculaire:C6H9N3O2
Pureté:95%+
Numéro de catalogue:CM104625
Poids moléculaire:155.16

Unité d'emballage Stock disponible Prix($) Quantité
CM104625-100g in stock ǜŵ
CM104625-500g in stock ŵưƎ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:6994-25-8
Formule moléculaire:C6H9N3O2
Point de fusion:-
Code SMILES:CCOC(=O)C1=CNN=C1N
Densité:
Numéro de catalogue:CM104625
Poids moléculaire:155.16
Point d'ébullition:349.2°C at 760 mmHg
N° Mdl:MFCD00005238
Stockage:Keep in dark place, store at 2-8°C.

Category Infos

Pyrazoles
Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
Pyrazone
Custom pyrazone for customers from all over the world are our main business.

Column Infos

Repotrectinib
Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.